Skip to content
Triangle logo TriangleGet started
← Back to this collection

PUBLICATIONS · 25888263

Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.

Open original source → · Download preserved record

Bibliographic metadata only. No full-text article or abstract is reproduced. Absence of a captured notice is not confirmation that a publication is clear of corrections or retractions.

Journal
Lancet Oncol
Publication date
2015 May
First author
Loriot Y

Publication notices

absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 May;16(5):477-8. doi: 10.1016/S1470-2045(15)70171-3.
    note
    Source null
    related pmid
    25888262
    relationship
    Comment in
  2. citation
    Nat Rev Urol. 2015 Jun;12(6):304. doi: 10.1038/nrurol.2015.94.
    note
    Source null
    related pmid
    25917887
    relationship
    Comment in

Authors and identifiers

  1. name
    Loriot Y
    type
    Author
  2. name
    Miller K
    type
    Author
  3. name
    Sternberg CN
    type
    Author
  4. name
    Fizazi K
    type
    Author
  5. name
    De Bono JS
    type
    Author
  6. name
    Chowdhury S
    type
    Author
  7. name
    Higano CS
    type
    Author
  8. name
    Noonberg S
    type
    Author
  9. name
    Holmstrom S
    type
    Author
  10. name
    Mansbach H
    type
    Author
  11. name
    Perabo FG
    type
    Author
  12. name
    Phung D
    type
    Author
Complete bibliographic record and source provenance
authors
  1. name
    Loriot Y
    type
    Author
  2. name
    Miller K
    type
    Author
  3. name
    Sternberg CN
    type
    Author
  4. name
    Fizazi K
    type
    Author
  5. name
    De Bono JS
    type
    Author
  6. name
    Chowdhury S
    type
    Author
  7. name
    Higano CS
    type
    Author
  8. name
    Noonberg S
    type
    Author
  9. name
    Holmstrom S
    type
    Author
  10. name
    Mansbach H
    type
    Author
  11. name
    Perabo FG
    type
    Author
  12. name
    Phung D
    type
    Author
bibliography ids
  1. nci-bib-0c3c3109e4a9dba70bb3dfdc
book metadata
content sha256
2065eb4d0aa3363adfe0e62ab77fc2db917decbd4b0237d88957bc6dbbd9de19
document type
citation
dois
  1. 10.1016/S1470-2045(15)70113-0
electronic publication date
display
2015 Apr 14
precision
day
year
2015
evidence scope
bibliographic_metadata_only
id
pubmed:25888263
immutable id
pubmed:25888263@2065eb4d0aa3363adfe0e62ab77fc2db917decbd4b0237d88957bc6dbbd9de19
journal
abbreviation
Lancet Oncol
issn electronic
1474-5488
issn print
1470-2045
issue
5
name
The Lancet. Oncology
nlm unique id
100957246
pages
509-21
volume
16
languages
  1. eng
notices
absence is not clearance
true
has correction metadata
false
has expression of concern metadata
false
has retraction in link
false
pubmed marks article retracted
false
pubmed marks retraction notice
false
relationships
  1. citation
    Lancet Oncol. 2015 May;16(5):477-8. doi: 10.1016/S1470-2045(15)70171-3.
    note
    Source null
    related pmid
    25888262
    relationship
    Comment in
  2. citation
    Nat Rev Urol. 2015 Jun;12(6):304. doi: 10.1038/nrurol.2015.94.
    note
    Source null
    related pmid
    25917887
    relationship
    Comment in
outcomes validated
false
pmid
25888263
provenance
batch id
74265f1b641f04cf2d05
provider
NCBI PubMed ESummary
record sha256
b593d596a2dab5b3e7c3599a542811d73e6cd4d2f9a481af0513d8ba7e3faca2
response sha256
193df6bb6d2ac41af73dc445bf8171fe8076a8c8a5e98882a3d6a1ada428b0f0
retrieved at
2026-09-09T23:47:10.134322+00:00
publication date
display
2015 May
precision
month
year
2015
publication types
  1. Clinical Trial, Phase III
  2. Journal Article
  3. Randomized Controlled Trial
  4. Research Support, Non-U.S. Gov't
record status
PubMed - indexed for MEDLINE
schema version
1.0
source url
https://pubmed.ncbi.nlm.nih.gov/25888263/
title
Effect of enzalutamide on health-related quality of life, pain, and skeletal-related events in asymptomatic and minimally symptomatic, chemotherapy-naive patients with metastatic castration-resistant prostate cancer (PREVAIL): results from a randomised, phase 3 trial.

Preserved source evidence · Not medical advice